SAN DIEGO--(BUSINESS WIRE)--Illumina (NASDAQ:ILMN - News) today announced the release of new sequencing chemistry kits and complementary software for its Genome Analyzer system. These new kits and software enable researchers to generate 40% more reads per run and extend read length to greater than 75 base pairs (bp). Also launched is the new Mate Pair Library Preparation Kit, which provides support for generating longer insert paired-end libraries and is complementary to Illumina’s existing short-end paired libraries. These new improvements enable researchers to generate 10 to 15 Gigabases (Gb) of high-quality data per run, more than doubling the output previously attainable on the Genome Analyzer.
“The availability of mate pair library kits and long paired-end reads has greatly increased the flexibility and capacity of our Illumina sequencers. I believe that they have greatly improved our ability to sequence cDNA libraries and may even open up the possibility to do de novo sequencing on the Illumina sequencer,” said W. Richard McCombie, Ph.D., Professor at the Cold Spring Harbor Laboratory. “They are also greatly helping our medical resequencing by giving us more data and the ability to look for small insertions and deletions in patient samples.”
Illumina’s unique combination of very high density and long reads allows researchers to economically take on a broad range of projects, such as whole human genome sequencing and de novo sequencing of complex organisms. In addition to the higher output and longer reads afforded by the new kits and software, Illumina’s flexible mate pair technique allows researchers to generate paired-end insert libraries measuring two to five kilobases (kb) to more comprehensively catalogue large structural variations. Coupled with Illumina’s standard paired-end insert libraries (200-500 bp), which are necessary for detection of smaller structural variants, these kits provide researchers with the most comprehensive set of library preparation tools for accurate and comprehensive sequencing and characterization of complex genomes.
“In addition to providing new solutions for de novo sequencing, the combination of short insert paired-end reads with the new longer insert mate pair sequencing is the most powerful approach for maximal coverage across the genome. This combination enables detection of the widest range of structural variant types and is essential for accurately identifying complex rearrangements,” said David Bentley, Vice-President and Chief Scientist of DNA Sequencing at Illumina.
Under an early access program, researchers at the National Center for Genome Resources (NCGR) have started working with the new long read and Mate Pair Library Kits. “At NCGR, the long read and mate pair chemistries are already enabling our cotton de novo and human resequencing projects. Four of our Genome Analyzers are now dedicated to 2 x 88 and 2 x 106 base pair runs, generating up to 20.5 Gigabases per run and a raw accuracy of greater than 99% over 106 base pairs. Additionally, we’re excited to use these improvements for structural variant detection and metagenomics,” said Greg May, Ph.D., Director of the Genome Center at NCGR.
Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, as well as individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. The Genome Analyzer offers the highest rate of daily output and the simplest, most user-friendly workflow. The Genome Analyzer supports the broadest set of applications, including those used to profile and discover novel transcripts, to create high-resolution genome-wide maps of DNA-protein binding sites and to sequence entire human genomes to greater than 30x coverage.
For more information about the Genome Analyzer and to read what customers are doing with Illumina’s sequencing technology, please visit http://www.illumina.com/sequencing.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
Contact:
Illumina Media: Maurissa Bornstein Public Relations Manager 858-332-4055 mbornstein@illumina.com Investors: Peter J. Fromen Sr. Director, Investor Relations 858-202-4507 pfromen@illumina.com
